



Date: 14.11.2025

To,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001.

Ref: Scrip Code: 526075

Sub: Outcome of the Board Meeting held on 14th November 2025

Dear Sir/Madam,

Pursuant to Regulation 33 and Regulation 30 read with Part-A of Schedule III of SEBI (LODR) Regulations, 2015, we hereby inform you that the Board of Directors of the Company at its Meeting held today i.e. 14th November, 2025 has inter-alia adopted and approved

- 1) The Standalone Un-Audited Financial Results for the Quarter and Half year ended on 30th September, 2025.
- 2) Limited Review Report by Statutory Auditors of the Company on Standalone Un-Audited Financial Results for the Quarter and Half year ended on 30th September, 2025.

The meeting of the Board of Directors commenced at 03:30 P.M. and concluded at 04:25 P.M.

This is for your information and record

Thanking you,

For Rekvina Laboratories Limited

Amit Mukesh Shah
Managing Director
DIN: 01993211

CIN: L24231GJ1988PLC01145

Regd. Office: 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Baroda -39007

Email Id: info@rekvinalaboratories.com, rekvinalimited@gmail.com

Cont. No.: 0265-2362966

REKVINA LABORATORIES LIMITED
CIN: L24231GJ1988PLC011458
Standalone Balance Sheet as at 30 September 2025

Rs. in Lacs

Particulars	Quarter Ended			Half year ended		Year Ended
	30 September 2025	30 June 2025	30 September 2024	30 September 2025	30 September 2024	31 March 2025
	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
ASSETS						
Non-current assets						
Current assets						
Financial Assets						
Cash and cash equivalents	0.18	3.26	9.96	0.18	9.96	2.51
Other current assets	7.28	7.44	-	7.28	-	0.41
Total Current Assets	7.46	10.70	9.96	7.46	9.96	2.92
Total Assets	7.46	10.70	9.96	7.46	9.96	2.92
II. EQUITY and LIABILITIES						
Equity Share Capital	301.40	301.40	301.40	301.40	301.40	301.40
Other Equity	(376.68)	(366.31)	(327.91)	(376.68)	(327.91)	(334.62)
Total Equity	(75.28)	(64.91)	(26.51)	(75.28)	(26.51)	(33.22)
Current liabilities						
Financial Liabilities						
Borrowings	81.23	75.40	24.87	81.23	24.87	24.68
Trade Payables						
- total outstanding dues of MSME	-	-	-	-	-	-
- total outstanding dues of others	0.31	(0.20)	11.51	0.31	11.51	10.39
Other current liabilities	1.19	0.42	0.09	1.19	0.09	1.07
Total Current liabilities	82.73	75.62	36.47	82.73	36.47	36.14
Total liabilities	82.73	75.62	36.47	82.73	36.47	36.14
Total Equity and Liabilities	7.45	10.71	9.96	7.45	9.96	2.92

For and on behalf of Board of Directors,
Rekvina Laboratories Limited

Mr. Amit Mukesh Shah
Managing Director
DIN: 01993211

Place: Vadodara
Date: 14.11.2025

REKVINA LABORATORIES LIMITED

CIN: L24231GJ1988PLC011458

Standalone Financial Result for the period ended on 30 September 2025

Rs. in Lacs

Sr No	Particulars	Quarter Ended			Half year ended		Year Ended
		30 September 2025	30 June 2025	30 September 2024	30 September 2025	30 September 2024	31 March 2025
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
I	Income						
	Revenue From Operations	19.62	-	-	19.62	-	-
	Total Income (I)	19.62	-	-	19.62	-	-
II	Expenses						
	Purchases of Stock-in-Trade	17.84	-	-	17.84	-	-
	Employee benefits expense	3.77	2.70	-	6.47	-	4.30
	Other expenses	1.50	0.84	6.65	2.34	7.00	9.41
	Total expenses (II)	23.11	3.54	6.65	26.65	7.00	13.71
III	Profit/(loss) before tax (I-II)	(3.49)	(3.54)	(6.65)	(7.03)	(7.00)	(13.71)
IV	Tax expense						
	Current tax	-	-	-	-	-	-
	Total Tax expense (IV)	-	-	-	-	-	-
V	Profit/(loss) after tax for the period (III-IV)	(3.49)	(3.54)	(6.65)	(7.03)	(7.00)	(13.71)
VI	Other Comprehensive Income						
	Total Other Comprehensive Income (VI)	-	-	-	-	-	-
VII	Total Comprehensive Income for the period (V+VI)	(3.49)	(3.54)	(6.65)	(7.03)	(7.00)	(13.71)
VIII	Earnings per equity share						
	Basic	0.06	0.06	0.11	0.12	0.12	0.23
	Diluted	0.06	0.06	0.11	0.12	0.12	0.23

For and on behalf of Board of Directors,
Rekvina Laboratories LimitedPlace: Vadodara
Date: 14.11.2025**Mr. Amit Mukesh Shah**
Managing Director
DIN: 01993211

REKVINA LABORATORIES LIMITED

CIN: L24231GJ1988PLC011458

Standalone Cash Flow Statement for the period ended on 30 September 2025

Rs. in Lacs

Particulars	Note No	For Period ended 30 September 2025	For Period ended 31 March 2025
CASH FLOWS FROM OPERATING ACTIVITIES			
Profit for the period/year		(7.03)	(13.71)
Adjustments for:			
Depreciation and amortisation		-	-
(Gain)/Loss on disposal of property, plant and equipment		-	-
(Gain)/Loss on disposal of Investments		-	-
(Gain)/Loss on investments measured at fair value through profit and loss		-	-
Provision for Income tax		-	-
Operating profit before working capital changes		(7.03)	(13.71)
Adjustment for (increase) / decrease in operating assets			
Trade receivables		-	-
Other assets		(6.87)	(0.41)
Adjustment for (Increase) / decrease in operating liabilities			
Trade payables		(10.07)	(1.04)
Employee benefit obligation		-	-
Other Liabilities		0.12	(4.02)
Cash generated from operations		(23.85)	(19.18)
Income tax paid (net)		-	-
Net cash generated by operating activities		(23.85)	(19.18)
CASH FLOWS FROM INVESTING ACTIVITIES			
Net cash (used in) / generated by investing activities		-	-
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from short term borrowings		56.55	20.74
Other Equity		(35.03)	-
Net cash used in financing activities		21.52	20.74
Net increase / (decrease) in cash and cash equivalents		(2.33)	1.56
Cash and cash equivalents at the beginning of the period/year		2.51	0.95
Exchange gain loss on Cash and cash equivalents		-	-
Cash and cash equivalents at the end of the year		0.18	2.51

For and on behalf of Board of Directors,
Rekvina Laboratories Limited**Mr. Amit Mukesh Shah**
Managing Director
DIN: 01993211Place: Vadodara
Date: 14.11.2025

Independent Auditor's Review Report on the Quarter Ended Un-Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to The Board of Directors

Rekvina Laboratories Limited.


1. We have reviewed the accompanying statement of unaudited standalone financial results of Rekvina Laboratories Limited (the "Company") for the 2nd quarter Ended 30th September 2025 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD1/44/2019, dated 29-03-2019. (The Circular).
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (IND AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2013 read with SEBI Circular No. CIR/CFD/CMD1/44/2019, is the responsibility of the Company's management and has been taken on record by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2014, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (IND AS) specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed or that it contains any material misstatement.
5. The accompanying IND AS financial results and other financial information for the corresponding quarter ended 30-09-2025, have been subject to a limited review or audit and based on the information compiled by Management and has been taken on record by the Board of Directors.

Date: 14.11.2025

Place: Vadodara



FOR Y. M. SHAH & Co.
Chartered Accountants
F. R. No.: 114124W


Yogesh Shah
Partner
M. No. 044305
UDIN: 25044305BMOQVB5451